Using Cardiac-Specific Biomarkers to Predict Cardiovascular Disease Risk Early

A new review article provides valuable insights into how traditional and emerging cardiac-specific biomarkers and their associated cardiovascular disease (CVD) risk factors may help point to effective preventive interventions in high-risk obese populations starting at an early stage of disease development. The growing problem of childhood obesity makes the identification of CVD biomarkers to identify early risk factors even more important, as noted in an article published in Metabolic Syndrome and Related Disorders, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Metabolic Syndrome and Related Disorders website through December 12, 2019.

Rajesh Parsanathan, PhD and Sushil K. Jain, PhD, Louisiana State University Health Sciences Center -Shreveport, coauthored the article entitled, “Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.” Based on their research, the authors state that while CVD risk markers in childhood obesity are a significant risk factor for CVD in adulthood, they have received too little attention.

The comprehensive review article focuses on traditional cardiac biomarkers as well as novel emerging cardiac-specific biomarkers, such as cardiac troponins, natriuretic peptides, heart-type fatty acid-binding protein, and miRNAs. In addition to biomarkers present in body fluids, the article discusses noninvasive anatomical and electrophysiological markers in cardiovascular disease and obesity.

“Childhood obesity is a growing problem which often enough translates into adult obesity. Both are associated with increased cardiovascular risk, and markers that predict this risk more accurately will allow us to target treatment to the subjects most at risk. This paper is a review of the current state of knowledge regarding such markers,” says Dr. Adrian Vella, Editor-in-Chief of Metabolic Syndrome and Related Disorders and Professor, Mayo Clinic College of Medicine, Rochester, MN.

About the Journal

Metabolic Syndrome and Related Disorders is the only peer-reviewed journal to focus solely on the pathophysiology, recognition, and treatment of metabolic syndrome. Led by Adrian Vella, MD, FRCP (Edin.), Professor of Medicine, Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, Rochester, MN, the Journal covers a range of topics including insulin resistance, central obesity, glucose intolerance, dyslipidemia with elevated triglycerides, predominance of small dense LDL-cholesterol particles, hypertension, endothelial dysfunction, and oxidative stress and inflammation. Complete tables of content and a sample issue may be viewed on the Metabolic Syndrome and Related Disorders website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Childhood Obesity, Diabetes Technology and Therapeutics, and Thyroid. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers website.

/Public Release. View in full here.